Rituximab in multiple sclerosis

Neurology

Volumn 87, Issue 20, 2016, Pages 2074-2081

  Salzer, Jonatan ^a   Svenningsson, Rasmus ^b,c   Alping, Peter ^b   Novakova, Lenka ^d   Björck, Anna ^b   Fink, Katharina ^b   Islam Jakobsson, Protik ^a   Malmeström, Clas ^d   Axelsson, Markus ^d   Vågberg, Mattias ^a   Sundström, Peter ^a   Lycke, Jan ^d   Piehl, Fredrik ^b   Svenningsson, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b Departments of Clinical Neuroscience and Clinical Sciences   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMUNOGLOBULIN G; NATALIZUMAB; RITUXIMAB; IMMUNOLOGIC FACTOR;

ACUTE CORONARY SYNDROME; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT; ARTICLE; BASAL CELL CARCINOMA; BRONCHITIS; CHILL; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FACIAL NERVE PARALYSIS; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; INFECTION; INFUSION RELATED REACTION; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NAUSEA; OBSERVATIONAL STUDY; OTITIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYODERMA GANGRENOSUM; RECURRENCE RISK; RHEUMATOID ARTHRITIS; SINUSITIS; TREATMENT DURATION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISABILITY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; SWEDEN; TREATMENT OUTCOME;

ADULT; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RETROSPECTIVE STUDIES; RITUXIMAB; SWEDEN; TREATMENT OUTCOME;

EID: 84995572377     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003331     Document Type: Article

References (20)

1. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688.
2. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460-471.
3. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsingremitting multiple sclerosis: a phase 2, randomised, placebocontrolled, multicentre trial. Lancet 2011;378:1779-1787.
4. Sorensen PS, Lisby S, Grove R, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology 2014;82:573-581.
5. Fyfe I. In the news: ocrelizumab excites ECTRIMS. Nat Rev Neurol 2015;11:667.
6. Alping P, Frisell T, Novakova L, et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 2016;79:950-958.
7. van Vollenhoven RF, Emery P, Bingham CO III, et al. Long-term safety of rituximab in rheumatoid arthritis: 9. 5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-1502.
8. Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-1164.
9. Sikkema T, Schuiling WJ, Hoogendoorn M. Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma. BMJ Case Rep 2013:2013.
10. Hillert J, Stawiarz L. The Swedish MS registry: clinical support tool and scientific resource. Acta Neurol Scand 2015;132:11-19.
11. Vagberg M, Lindqvist T, Ambarki K, et al. Automated determination of brain parenchymal fraction in multiple sclerosis. AJNR Am J Neuroradiol 2013;34: 498-504.
12. Kim JW, Min CK, Mun YC, et al. Varicella-zoster virusspecific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib-or thalidomide-based chemotherapy. J Clin Virol 2015;73: 64-69.
13. Salzer J, Lycke J, Wickstrom R, Naver H, Piehl F, Svenningsson A. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol 2016;263:322-326.
14. PRISMS Study Group and the University of British ColumbiaMS/ MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56: 1628-1636.
15. Willis MD, Harding KE, Pickersgill TP, et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multicentre cohort. Mult Scler 2016;22:1215-1223.
16. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014;85:1190-1197.
17. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 2015;72:152-158.
18. Frisell T, Forsberg L, Nordin N, et al. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Mult Scler 2016;22:85-93.
19. McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016;87: 117-125.
20. Hauser SL. The Charcot Lecture: beating MS: a story of B cells, with twists and turns. Mult Scler 2015;21:8-21.